How the Right Starting Materials Can Deliver a Higher Probability of Attaining Cell & Gene Therapy Manufacturing Success

Time: 11:45 am
day: Agenda: Next Generation of Cell Therapies: Combined Analytics & Cryopreserved Starting Materials


  • Outline how characterized donor source materials can impact consistency from process development to manufacturing
  • Strategies for building efficiencies and alleviate bottlenecks by implementing cryopreserved leukapheresis
  • Requirements to delivering a sustainable starting material supply chain for large-scale allogeneic therapies